On Sept. 4, the U.S. Food and Drug Administration (FDA) approved Xuriden (uridine triacetate), the first FDA-approved treatment for patients with hereditary orotic aciduria, a rare metabolic disorder that has been reported in about 20 patients worldwide.
© 2021 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder
